Hamza Thindal Capital Corporation is Appointed to Provide Investor Relations Services for biOasis


VANCOUVER, British Columbia, Aug. 16, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that it has entered into a consulting agreement with Hamza Thindal Capital Corporation Inc. ("Hamza Thindal") for Hamza Thindal to provide investor relations services to the Company.

Hamza Thindal is an established investor relations Company based in Surrey, BC and has successfully demonstrated the ability to work with junior companies in articulating a company's inherent value to strategic partners and the investment community.

"Hamza Thindal Capital Corporation will work with management to disseminate and communicate to members of the financial community, to potential investors and to current shareholders on the activities and advances made by the Company on a regular basis," says biOasis President and CEO, Rob Hutchison. "We believe that professional investor relations services are an important tool available to the Company to help improve valuation and liquidity of our publicly traded shares."

The Agreement is for a term of one year and may be terminated by either party by giving 30 days' written notice of such termination. The Company will pay a consulting fee to Hamza Thindal of $5,000 per month plus HST plus approved expenses incurred on behalf of the Company. The Company has also granted HTC 100,000 incentive options to purchase shares of the Company at a price of $0.48 per share for a period of two years. The options are subject to vesting as follows: 25,000 three months after the date of grant and 25,000 each three months thereafter. The options will follow the guidelines set out in the Company's stock option plan and as set forth by TSX Venture Exchange policy. Both the options and the investor relations consulting agreement are subject to the approval of the TSX Venture Exchange.

About Hamza Thindal Capital Corporation:

Hamza Thindal is owned by Dr. Essam Hamza, MD and Mr. Kamaldeep Thindal, both of Surrey, British Columbia, Canada. The Company consults with a small number of junior public emerging companies to provide capital markets consulting, fundraising, and investor relations in a variety of industries and sectors. They leverage business acumen, capital markets experience and access to finance to help companies achieve their goals.

ABOUT BIOASIS:

biOasis Technologies Inc. is a Biopharmaceutical company focused on the Health Care & Life Sciences market and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases. It has extensive and comprehensive intellectual property ("IP"), which it obtained from The University of British Columbia. The Company's initial area of focus has been on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer's disease ("Cognitest™"). This IP has been corroborated in double-blinded and successive multi-site human sample trials.

The Company is also accelerating its work on its Blood-Brain Barrier Therapeutic delivery platform ("Transcend™") that has been independently verified to shuttle a variety of therapeutic compounds across the Blood-Brain Barrier. 

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Robin Hutchison

Director and CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"



            

Contact Data

GlobeNewswire